News
RDIF and ChemRar have produced the first 100,000 courses of Avifavir
In June Avifavir was delivered across Russia’s ...
02.07.2020
Moscow, June 11, 2020 - The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and the ChemRar ...
11.06.2020
Moscow, June 8, 2020 - The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and the ChemRar Group ...
08.06.2020
Avifavir is one of the two registered COVID-19 drugs in the world
Avifavir is the first drug registered in Russia ...
03.06.2020
Avifavir is the first direct-acting antiviral drug registered in Russia that has proven effective against COVID-19 in ...
01.06.2020
Median elimination of the virus in four days compared to nine days with standard therapy, according to the study ...
22.05.2020
Moscow, May 13, 2020 - The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and the ChemRar Group ...
14.05.2020
Russia is set to test the antiviral drug Favipiravir as a treatment for COVID-19 following "excellent results" in ...
07.04.2020
The drug has been used successfully in China to cure coronavirus patients
Moscow, March 26, 2020 – The Supervisory ...
26.03.2020
Avineuro Project from ChemRar Research Institute has finished the multicenter, randomized, double-blind, ...
27.11.2019
BIOTECHMED 2019 Forum that involved representatives of ChemRar Group and international accelerator biobridge-2019, ...
27.11.2019
The international accelerator biobridge-2019 has established a special nomination for the finalists of the Startup ...
27.11.2019